As filed with the Securities and Exchange Commission on March 20, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT ...

Edinburgh, United Kingdom, March 20, 2024 (GLOBE NEWSWIRE) – NuCana plc (NASDAQ: NCNA) announced financial results for the fourth quarter and year ended December 31, 2023 and provided an update on its broad clinical development program with its transformative ProTide therapeutics. Exhibit 99.1 NuCana Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update Announced Encouraging Updates from NUC-3373 and NUC-7738 Demonstrating Promising Ef icacy and Safety Pipeline Continues to ...

Exhibit 99.1 NUCANA PLC UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | | | For the Three Months Ended | | For the Nine Months Ended | | | --- | --- | --- | --- | --- | --- | | | | September 30, | | September 30, | | | | Notes | 2023 | 2022 | 2023 | 2022 | | | | | (in thousands, except per share data) | | | | | | ਣ | | キ | ਦੇ | | Research and development expenses | | (7,439) | (7,386) | (18,203) | (23,238) | | Administrative expenses | | (1,375) | (1,715) | (4,777) | (5,756) | | Net foreign exch ...

Exhibit 99.1 NUCANA PLC UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | | | For the Three Months Ended March 31, | | | --- | --- | --- | --- | | | Notes | 2023 | 2022 | | | | (in thousands, except per share data) | | | | | £ | £ | | Research and development expenses | | (6,805) | (9,446) | | Administrative expenses | | (1,648) | (2,152) | | Net foreign exchange (losses) gains | | (695) | 1,131 | | Operating loss | | (9,148) | (10,467) | | Finance income | | 287 | 31 | | Loss before tax | | (8,86 ...

A New Era in Oncology Limitations of Nucleoside Analogs Peak Year Sales 16 FDA Approved Anti-Cancer Nucleoside Drugs Activation Inefficient generation of anti-cancer metabolites 4 HIV Genvoya® 150 mg / 150 mg 200 mg / 10 mg film-coated tablets Elvitegravir/cobicistat/ Genvoya® emtricitabine/ tenofovir alafenamide 50 mg / 150 mg 30 film-coated tablets ericitabin Grail use (I GILEAD ¹ Sovaldi + Harvoni + Epclusa + Vosevi cumulative sales through 31 December 2022 2 Genvoya + Descovy + Odefsey + Biktarvy + Symt ...

As filed with the Securities and Exchange Commission on April 4, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT ...

Financial Performance - The net loss for Q4 2022 was £15.2 million, compared to a net loss of £13.6 million for Q4 2021; the net loss for the year 2022 was £32.0 million, an improvement from £40.5 million in 2021[3]. - Basic and diluted loss per share for Q4 2022 was £0.29, compared to £0.26 for Q4 2021; for the year 2022, it was £0.61, down from £0.78 in 2021[3]. - The operating loss for the year was £17,248,000, compared to £15,737,000 in 2021, indicating an increase in losses of 10%[10]. - The loss for the period was £15,199,000, compared to £13,644,000 in 2021, which is an increase of 11%[10]. - Basic and diluted loss per share for the year was £0.29, compared to £0.26 in the previous year, indicating a worsening of 12%[10]. - The company reported a net loss for the period of £40.5 million, compared to £33.3 million in the previous year, indicating a year-over-year increase of approximately 21.6% in losses[12]. Cash and Liquidity - As of December 31, 2022, NuCana reported cash and cash equivalents of £41.9 million, down from £50.8 million as of September 30, 2022, and £60.3 million at December 31, 2021[3]. - NuCana's cash runway is anticipated to fund operations into 2025, supporting ongoing clinical programs[4][9]. - Cash used in operations was £30.4 million, a decrease from £33.7 million in the prior year, reflecting an improvement in operational efficiency[12]. - The company experienced a net cash used in investing activities of £120,000, compared to £3.5 million in the previous year, showing a significant reduction in investment outflows[12]. - Interest received was £6.3 million, a notable increase from £1.2 million year-over-year, indicating improved cash management strategies[12]. - The company reported a decrease in prepayments and accrued income of £30.7 million, reflecting tighter cash flow management[12]. - The net cash from financing activities was £66.2 million, indicating strong capital raising efforts through share issuance[12]. - Cash and cash equivalents at the beginning of the year were $60.26 million, with an effect of exchange rate changes on cash and cash equivalents amounting to $4.84 million[9]. - Cash and cash equivalents at the end of the year were $41.91 million, reflecting a decrease of $23.19 million[9]. Assets and Liabilities - Total assets as of December 31, 2022, amounted to £58,254,774, which is an increase from £57,474,000 in 2021[11]. - Non-current assets, including intangible assets, were valued at £23,652,410, compared to £24,100,000 in the previous year[11]. - Current assets totaled £39,574,161, showing a growth from £41,616,000 in 2021[11]. - Total equity attributable to equity holders of the company was £38,502,265, up from £35,548,000 in 2021[11]. - Current liabilities, including trade payables, were £48,031,829, reflecting an increase from £48,290,000 in the previous year[11]. - Total liabilities amounted to £19,752,121, which is an increase from £19,926,000 in 2021[11]. - The company reported accumulated deficit of £180,573, compared to £149,726 in the previous year[11]. - Provisions for liabilities were recorded at £4,100,000, consistent with the previous year[11]. - The company’s total equity and liabilities were £58,254,774, indicating a stable financial position[11]. Research and Development - NuCana plans to announce data from three clinical studies of NUC-3373 in 2023, including a Phase 2 study with 171 patients comparing NUFIRI plus bevacizumab to standard care[4][7]. - The company expects to provide updates on the Phase 2 part of the NuTide:701 study for NUC-7738, investigating its use as a monotherapy and in combination with pembrolizumab[4][7]. - The company achieved significant development milestones for NUC-3373 and NUC-7738 in 2022, progressing both to Phase 2 development[4]. - NUC-3373 is being evaluated for its potential to replace 5-FU across multiple tumor types, with ongoing studies aimed at optimizing treatment combinations[4][6]. - The NuTide:323 study aims to provide meaningful data for second-line colorectal cancer patients, potentially influencing future Phase 3 study designs[4][7]. Expenses - Research and development expenses for the year ended December 31, 2022, were £13,188,000, compared to £10,634,000 for the previous year, representing a 24% increase[10]. - Administrative expenses increased to £1,535,000 in 2022 from £2,073,000 in 2021, showing a decrease of 26%[10].

Favorable Pharmacokinetic Profile Number of patients | --- | --- | --- | |--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------|----------------------------------------------------------| | Metastatic Colorectal Cancer | Metastatic Basal Cell Carci ...

Exhibit 99.1 NUCANA PLC UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | | | For the Three Months Ended | | For the Nine Months Ended | | | --- | --- | --- | --- | --- | --- | | | | September 30, | | September 30, | | | | Notes | 2022 | 2021 | 2022 | 2021 | | | | | (in thousands, except per share data) | | | | | | £ | £ | £ | £ | | Research and development expenses | | (7,386) | (8,971) | (23,238) | (26,200) | | Administrative expenses | | (1,715) | (2,277) | (5,756) | (6,456) | | Net foreign exc ...

| --- | --- | |-------|--------------------------------------| | | | | | | | | | | | Corporate Presentation | | | February 2021 Corporate Presentation | | | September 2022 | Disclaimer Forward-Looking Statements This presentation contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the "Company"). All statements other than statements of ...